Kintegral Advisory’s BioMarin Pharmaceuticals BMRN Stock Holding History

Kintegral Advisory’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,213	Closed	-$442K	–	267
2022 Q3	$442K	Hold	5,213	–	–	0.06%	222
2022 Q2	$432K	Buy	5,213 +110	+2%	+$8.76K	0.06%	228
2022 Q1	$393K	Buy	5,103 +114	+2%	+$9.54K	0.04%	247
2021 Q4	$441K	Hold	4,989	–	–	0.05%	239
2021 Q3	$386K	Hold	4,989	–	–	0.05%	245
2021 Q2	$416K	Hold	4,989	–	–	0.05%	247
2021 Q1	$377K	Hold	4,989	–	–	0.05%	251
2020 Q4	$437K	Hold	4,989	–	–	0.06%	232
2020 Q3	$380K	Sell	4,989 -161	-3%	-$16.3K	0.06%	225
2020 Q2	$635K	Hold	5,150	–	–	0.1%	170
2020 Q1	$435K	Buy	5,150 +577	+13%	+$49.7K	0.08%	197
2019 Q4	$387K	Hold	4,573	–	–	0.07%	229
2019 Q3	$308K	Hold	4,573	–	–	0.06%	254
2019 Q2	$392K	Hold	4,573	–	–	0.08%	224
2019 Q1	$406K	Buy	4,573 +205	+5%	+$19K	0.09%	210
2018 Q4	$372K	Buy	+4,368	New	+$416K	0.11%	163

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Kintegral Advisory's BMRN Position: Q4 2022 in Review

Kintegral Advisory sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2022, closing a stake of 5,213 shares — an estimated $442K sold.

Kintegral Advisory first reported a position in BMRN in Q4 2018 and held it in 16 quarters. The position peaked at $635K in Q2 2020. 580 funds tracked by Wall St. Rank hold BMRN as of Q4 2022.

Kintegral Advisory reported no remaining BioMarin Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Kintegral Advisory sold 5,213 BioMarin Pharmaceuticals shares in Q4 2022, an estimated $442K.
Kintegral Advisory first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 16 quarters.
Kintegral Advisory's BioMarin Pharmaceuticals position peaked at $635K in Q2 2020.
580 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2022.

Based on Kintegral Advisory's 13F filing for Q4 2022, filed 14 Feb 2023.